This case highlights the existence of this unique type of GBM-PNC and, through a literature review, suggests that MYC amplification could serve as an early predictive biomarker for CSF dissemination, offering valuable insights for early prevention and management of ECM in GBM. This evidence concerns the gene MYC and glioblastoma.